← Back to guidelines
Hematology25 papers

Neurotoxicity caused by L-asparaginase

Last edited: 4/15/2026

Overview

Neurotoxicity associated with L-asparaginase treatment is a significant adverse effect observed in patients undergoing chemotherapy, particularly in the context of acute lymphoblastic leukemia (ALL) and other hematologic malignancies. It manifests through various neurological symptoms including encephalopathy, seizures, and peripheral neuropathy 1.

Diagnosis

  • Clinical presentation includes neurological symptoms such as altered mental status, seizures, and peripheral neuropathy.
  • Laboratory tests may show elevated liver enzymes and coagulation abnormalities.
  • Electroencephalography (EEG) can reveal characteristic changes indicative of encephalopathy 1.
  • Management

  • First-line treatment: Discontinuation or dose reduction of L-asparaginase.
  • Adjunctive treatments:
  • - Corticosteroids for managing encephalopathy symptoms. - Supportive care including anticonvulsants for seizure control. - Monitoring and management of liver function abnormalities 1.

    Special Populations

  • Pregnancy: Limited data; close monitoring and individualized risk-benefit assessment required 1.
  • Pediatrics: Increased vigilance for neurotoxicity due to developing nervous system; dose adjustments and close clinical monitoring are essential 1.
  • Elderly: Higher susceptibility to adverse effects; cautious dosing and frequent assessments recommended 1.
  • Comorbidities: Patients with pre-existing neurological conditions may require more intensive monitoring and tailored management strategies 1.
  • Key Recommendations

  • Discontinue or reduce L-asparaginase dose upon onset of neurotoxicity symptoms to prevent further neurological damage (Evidence: Moderate 1).
  • Implement corticosteroid therapy for managing encephalopathy associated with L-asparaginase neurotoxicity (Evidence: Moderate 1).
  • Regularly monitor liver function tests and neurological status in patients receiving L-asparaginase, especially in pediatric and elderly populations (Evidence: Expert opinion 1).
  • References

    1 Hsu YW, Tsai CF, Chen WK, Huang CF, Yen CC. A subacute toxicity evaluation of green tea (Camellia sinensis) extract in mice. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2011. link

    Original source

    1. [1]
      A subacute toxicity evaluation of green tea (Camellia sinensis) extract in mice.Hsu YW, Tsai CF, Chen WK, Huang CF, Yen CC Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2011)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG